美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

新橋生物

2.98

+0.07502.59%

成交量：42.06萬

成交額：122.79萬

市值：3.43億

市盈率：-9.86

高：3.01

開：2.90

低：2.89

收：2.90

52周最高：6.79

52周最低：0.5950

股本：1.15億

流通股本：4,823.40萬

量比：1.24

換手率：0.87%

股息：- -

股息率：- -

每股收益(TTM):-0.3017

每股收益(LYR):-0.2738

淨資產收益率：-18.46%

總資產收益率：-10.36%

市淨率：1.32

市盈率(LYR):-10.87

資料載入中...

總覽公司新聞資訊公告

新橋生物：預計最早於2026年第四季度啓動註冊性三期聯合試驗

新橋生物：FDA確認Givastomig有望符合加速審批資格

新橋生物計劃於2026年第四季度啓動以客觀緩解率為主要終點的註冊性三期聯合試驗

新橋生物宣佈與FDA就胃腺癌藥物Givastomig加速審批路徑達成建設性B類會議

BUZZ--美國股票走勢-Hims & Hers、Live Nation、NovaBridge

BUZZ-NovaBridge 股價上漲，因眼病藥物中期試驗顯現前景

新橋生物公布二期a階段頂線數據：Vis-101為濕性年齡相關性黃斑變性提供快速、強勁且持久的治療反應

新橋生物Vis-101試驗結果亮眼：平均BCVA改善超10個ETDRS字母，中位CST降低100-150微米

中東歐市場：波蘭央行下調基準利率後，茲羅提保持漲勢

环球市场播报

新橋生物任命生物技術領袖埃米特·T·坎寧安博士為董事會副主席，加速全球生物技術平台發展

新橋生物全球首例患者入組：Givastomig聯合免疫化療治療一線轉移性胃癌的隨機二期研究啓動

新橋生物盤中異動早盤急速下挫5.19%

華爾街頂級分析師最新評級：亞馬遜遭下調，羅布樂思獲上調

环球市场播报

BUZZ--美國股票走勢-Shake Shack、Arrowhead 製藥公司、洛歇馬丁公司

BUZZ--美國股票走勢-Alkermes、Ball Corp、NovaBridge

BUZZ-癌症藥物在早期試驗中顯示出前景，NovaBridge 公司業績上升

新橋生物公布Givastomig Ib期劑量擴展研究突破性成果；低至25美元/月，諾和諾德口服GLP-1上市！

新橋生物聯合療法耐受性良好安全性媲美現行標準治療方案

新橋生物聯合療法安全性特徵與既往觀察相似，免疫相關性胃炎引發關注

新橋生物公布Givastomig聯合療法一線治療轉移性胃癌IB期劑量擴展積極數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NBP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"新橋生物","latestPrice":2.975,"timestamp":1773762814159,"preClose":2.9,"halted":0,"volume":420581,"delay":0,"changeRate":0.025862068965517303,"floatShares":48234000,"shares":115266053,"eps":-0.30172,"marketStatus":"交易中","change":0.075,"latestTime":"03-17 11:55:01 EDT","open":2.9,"high":3.0092,"low":2.89,"amount":1227863.3078355,"amplitude":0.041103,"askPrice":2.98,"askSize":481,"bidPrice":2.97,"bidSize":605,"shortable":3,"etf":0,"ttmEps":-0.30172,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1773777600000},"marketStatusCode":2,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":2.9,"preHourTrading":{"tag":"盘前","latestPrice":2.91,"preClose":2.9,"latestTime":"09:29 EDT","volume":2218,"amount":6477.674323200001,"timestamp":1773754141014,"change":0.01,"changeRate":0.003448,"amplitude":0.013793},"postHourTrading":{"tag":"盘后","latestPrice":2.9,"preClose":2.9,"latestTime":"19:53 EDT","volume":332,"amount":962.0665,"timestamp":1773705221273,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.242784,"impliedVol":0.507,"impliedVolPercentile":0.0638},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":48234000,"roa":"-10.36%","roe":"-18.46%","lyrEps":-0.273814,"volumeRatio":1.242784,"shares":115266053,"dividePrice":0,"high":3.0092,"amplitude":0.041103,"preClose":2.9,"low":2.89,"week52Low":0.595,"pbRate":"1.32","week52High":6.79,"institutionHeld":0,"latestPrice":2.975,"committee":0.11418,"eps":-0.30172,"divideRate":0,"volume":420581,"delay":0,"ttmEps":-0.30172,"open":2.9,"prevYearClose":3.98,"prevWeekClose":2.83,"prevMonthClose":3.28,"prevQuarterClose":3.98,"fiveDayClose":3.24,"twentyDayClose":3.22,"sixtyDayClose":4.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"NBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2024-08-28","symbol":"NBP","fiscalQuarterEnding":"2024/06","expectedEps":-0.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1724817600000,"reportTimeType":"pre","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1759723200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-03-13","current":-9.61156,"percent":0.688889,"low":-20.276437,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"high":-10.607129,"avg":-14.558462,"sd":2.42633,"marketCap":338955631},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631}],"updateTime":1773734801566},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1164386189","title":"新橋生物：預計最早於2026年第四季度啓動註冊性三期聯合試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1164386189","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164386189?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 20:42","pubTimestamp":1773664949,"startTime":"0","endTime":"0","summary":"新桥生物宣布，公司计划最早在2026年第四季度开展一项注册性三期联合临床试验。这一关键进展标志着其在创新疗法开发道路上迈出重要一步，为后续商业化布局奠定基础。通过将不同治疗机制相结合，该试验旨在探索更优临床效果，为患者提供突破性治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"1120501405","title":"新橋生物：FDA確認Givastomig有望符合加速審批資格","url":"https://stock-news.laohu8.com/highlight/detail?id=1120501405","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120501405?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 20:39","pubTimestamp":1773664740,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式确认，新桥生物（NovaBridge Biosciences）旗下在研药物Givastomig具备潜在资格，有望通过加速审批通道推进上市进程。\n这一进展意味着，若后续临床试验数据积极，Givastomig或可基于替代终点提前获批，从而缩短其进入市场的时间。加速审批路径通常适用于针对严重疾病、且现有治疗选择有限的创新疗法。\n新桥生物表示，将继续与FDA保持密切沟通，积极推进Givastomig的临床开发计划，以期早日为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"1139570168","title":"新橋生物計劃於2026年第四季度啓動以客觀緩解率為主要終點的註冊性三期聯合試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1139570168","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139570168?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:03","pubTimestamp":1773658990,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，公司将于2026年第四季度正式启动一项注册性三期联合疗法临床试验。该试验将采用客观缓解率（ORR）作为主要疗效终点，旨在评估创新疗法组合在目标患者群体中的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"1106527073","title":"新橋生物宣佈與FDA就胃腺癌藥物Givastomig加速審批路徑達成建設性B類會議","url":"https://stock-news.laohu8.com/highlight/detail?id=1106527073","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106527073?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:02","pubTimestamp":1773658924,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）近日披露，该公司与美国食品药品监督管理局（FDA）针对其在研药物Givastomig用于治疗胃腺癌的加速批准路径，成功举行了一场富有成效的B类会议。\n此次会议重点探讨了Givastomig通过加速审批通道上市的可能性，双方就后续临床开发策略及数据要求达成重要共识。该进展标志着Givastomig在胃腺癌治疗领域的商业化进程迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2618621524","title":"BUZZ--美國股票走勢-Hims & Hers、Live Nation、NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621524","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621524?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 21:30","pubTimestamp":1773063020,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4S3ZX1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","PLD","FCEL","COP","LYV","SATS","XOMX","HL","BARC.UK","HIMS","DTIL","AAL","IE00B2Q91V27.USD","COHX","SATG","LUV","VRT","LITX","LU0170899867.USD","XOMZ","XENE","NBP","SLB","CDE","AGH","ITT","DAL","NEM","LU0433182093.SGD","NWMX","HMYY","RAPP","VRTL","AALG","AU","PFE","XOMO","NEMG","HIYY","LU0162691827.USD","UAL","HIMY","LU1894683264.USD","CAT","RLMD","LU2462611646.USD"],"gpt_icon":1},{"id":"2618628305","title":"BUZZ-NovaBridge 股價上漲，因眼病藥物中期試驗顯現前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628305","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628305?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 19:17","pubTimestamp":1773055079,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4T3ZX11X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"1184660068","title":"新橋生物公布二期a階段頂線數據：Vis-101為濕性年齡相關性黃斑變性提供快速、強勁且持久的治療反應","url":"https://stock-news.laohu8.com/highlight/detail?id=1184660068","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184660068?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 19:02","pubTimestamp":1773054152,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）最新发布的二期a阶段临床试验顶线数据显示，其核心候选药物Vis-101在治疗湿性年龄相关性黄斑变性（wet AMD）方面展现出卓越疗效。研究结果表明，该疗法能诱导快速起效、强劲且持久的治疗反应，为患者提供了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"1179612326","title":"新橋生物Vis-101試驗結果亮眼：平均BCVA改善超10個ETDRS字母，中位CST降低100-150微米","url":"https://stock-news.laohu8.com/highlight/detail?id=1179612326","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179612326?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 19:02","pubTimestamp":1773054140,"startTime":"0","endTime":"0","summary":"新桥生物近日公布了其候选药物Vis-101的临床试验数据，结果显示其在治疗相关眼部疾病方面取得了显著成效。\n数据显示，接受Vis-101治疗的患者群体，其最佳矫正视力出现了具有临床意义的提升，平均改善幅度超过了10个ETDRS字母。与此同时，患者的中位中心凹厚度也呈现出显著下降，降低范围在100至150微米之间。\n这些积极的数据指标，为Vis-101后续的临床开发路径提供了有力的支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2616551655","title":"中東歐市場：波蘭央行下調基準利率後，茲羅提保持漲勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2616551655","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616551655?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 23:14","pubTimestamp":1772637240,"startTime":"0","endTime":"0","summary":"波兰央行周三如期下调基准利率，波兰兹罗提维持涨势。此前，随着以色列与美国袭击伊朗后冲突升级，市场对此次降息的预期愈发存疑。　　波兰央行周三将主要利率下调 25 个基点至 3.75%。波兰央行行长定于周四召开新闻发布会。　　捷克央行副行长扬弗赖特周三发表评论称，伊朗袭击事件的后续影响可能限制捷克降息空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-04/doc-inhpvyee3702700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["UTHY","UFIV","UTWY","FRA","EURmain","UBmain","USVN","UTRE","TNmain","NBP","ZNmain","ZTmain","BK4139","FXE","MEURmain","ZFmain","EUO","ZBmain"],"gpt_icon":0},{"id":"1132480297","title":"新橋生物任命生物技術領袖埃米特·T·坎寧安博士為董事會副主席，加速全球生物技術平台發展","url":"https://stock-news.laohu8.com/highlight/detail?id=1132480297","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132480297?lang=zh_tw&edition=fundamental","pubTime":"2026-02-19 20:02","pubTimestamp":1771502522,"startTime":"0","endTime":"0","summary":"新桥生物宣布任命生物技术领域的杰出领导者埃米特·T·坎宁安博士为董事会副主席。这一重要人事任命旨在进一步加速公司全球生物技术平台的拓展与创新。坎宁安博士在医学、科研及公共卫生领域拥有深厚的学术背景和丰富的行业经验，他的加入将为新桥生物的战略发展注入强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"1106070252","title":"新橋生物全球首例患者入組：Givastomig聯合免疫化療治療一線轉移性胃癌的隨機二期研究啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1106070252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106070252?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 05:07","pubTimestamp":1771362463,"startTime":"0","endTime":"0","summary":"新桥生物宣布，其全球性、随机二期临床研究已完成首例患者给药。该研究旨在评估Givastomig与免疫化疗联合方案，用于一线治疗转移性胃癌患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2610254671","title":"新橋生物盤中異動 早盤急速下挫5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610254671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610254671?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 22:46","pubTimestamp":1770734803,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时46分，新桥生物股票出现波动，股价快速跳水5.19%。截至发稿，该股报3.29美元/股，成交量6.1783万股，换手率0.05%，振幅6.14%。新桥生物股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.涨幅较大，Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃，换手率分别为1388.98%、724.16%、639.30%，振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Lunai Bioworks Inc.，振幅分别为58.92%、31.58%、22.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210224643a49411ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210224643a49411ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2609188205","title":"華爾街頂級分析師最新評級：亞馬遜遭下調，羅布樂思獲上調","url":"https://stock-news.laohu8.com/highlight/detail?id=2609188205","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609188205?lang=zh_tw&edition=fundamental","pubTime":"2026-02-07 00:42","pubTimestamp":1770396120,"startTime":"0","endTime":"0","summary":"华尔街最受关注、对市场影响显著的分析师研报评级调仓信息汇总如下。罗布乐思：自由资本将其评级从持有上调至买入，目标价维持 85 美元不变。受股价较 52 周高点回落 25% 影响，当前估值具备优势，成为机构上调评级的核心原因。因公司当前股价已高于机构目标价，估值偏高成为此次评级下调的主因。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"7e2ce814132396a12bf08afb828778ef","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-07/doc-inhkxcfv7836258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1244550577.SGD","LU2111349929.HKD","LU1116320901.HKD","LU2360032135.SGD","LU2505996509.AUD","LU0320765059.SGD","LU0267386448.USD","LU0353189680.USD","BK4612","BK4538","LU2361045086.USD","LU0109392836.USD","LU0345768153.USD","LU0943347566.SGD","SG9999014898.SGD","LU2237957811.SGD","LU2362541273.HKD","BK4565","IE00BWXC8680.SGD","LU0390134368.USD","IE00BMPRXN33.USD","LU1935042215.USD","IE0001KFT4U8.USD","LU0861579265.USD","LU1720051017.SGD","NBP","AMZU","SNAP","BK4534","EL","LU0256863811.USD","IE0004086264.USD","LU1235294995.USD","BK4598","IE00BFXG0V08.USD","BK4551","LU1989764748.USD","LU0640476718.USD","LU2543165471.USD","LU0314104364.USD","BK4507","LU0072461881.USD","USAW.SI","IE000KEQY171.SGD","LU1066051498.USD","SG9999000418.SGD","AMZY","IE00BJTD4N35.SGD","ROKU","IE00BQXX3F31.USD","IE00B5949003.HKD","LU0210528500.USD","LU0980610538.SGD","SG9999002232.USD","LU2456880835.USD","LU1934455194.USD","IE00BQXX3D17.EUR","LU0823421416.USD","LU1803068979.SGD","LU2361044949.HKD","HUBG","SGXZ31699556.SGD","LU0889565833.HKD","LU1674673691.USD","LU0823434740.USD","LU1066051811.HKD","LU0170899867.USD","LU2430703251.USD","LU2462157665.USD","LU2065171402.SGD","SG9999001077.SGD","IE0009356076.USD","LU0211327993.USD","LIN","LU0965509010.AUD","LU0345774391.USD","RBLX","LU1691799644.USD","BOOT","BK4533","SG9999014906.USD","LU1868837136.USD","BK4527","LU1127390331.HKD","LU2430703095.HKD","LU1116320737.USD","LU2487616109.SGD","LU2237957902.USD","LU1917777945.USD","LU1119994496.HKD","LU0345770308.USD","LU2023251221.USD","LU0342679015.USD","SG9999018857.SGD","LU0048584097.USD","SG9999018865.SGD","LU1974910355.USD","BK4604","LU2317271919.USD","LU0672654240.SGD","LU0130103400.USD","LU1074936037.SGD","LU0149725797.USD","IE00BKVL7J92.USD","LU1435385759.SGD","SG9999015952.SGD","LU0203201768.USD","BK4596","LU0719512351.SGD","LU0964807845.USD","LU2720916845.USD","LU2860962120.EUR","IE0005OL40V9.USD","LU2552382215.SGD","IE00BJLML261.HKD","LU0128525929.USD","LU0320765489.SGD","LU1153585028.USD","LU1429558221.USD","LU1066051225.USD","LU1064131342.USD","IE0009G5SDU7.USD","LU2089284900.SGD","LU0203202063.USD","LU0061474705.USD","BK4543","IE00B5TLWC47.USD","IE00BJTD4V19.USD","LU0708995401.HKD","LU1934455863.HKD","LU2242649171.HKD","LU0882574139.USD","LU0011850046.USD","LU2326559502.SGD","AMZD","LU1914381329.SGD","LU2063271972.USD","LU0316494557.USD","LU1201861249.SGD","IE00BN29S564.USD","LU2362541513.USD","LU2265009873.SGD","PI","IE00B3SWFQ91.USD","SGXZ99366536.SGD","LU2087625088.SGD","BK4085","LU0985320562.USD","IE00B19Z3581.USD","BK4547","IE0003U64NQ7.SGD","LU0787776722.HKD","LU0082616367.USD","BK4532","LU1935042991.SGD","LU0061474960.USD","LU0345769128.USD","LU1935043536.SGD","LU2420271590.USD","IE00B19Z9505.USD","LU0354030438.USD","LU2361044865.SGD","LU1496350171.SGD","MMSI","LU0708994859.HKD","LU0210536198.USD","LU1839511570.USD","LU2168564065.EUR","IE00BYQQ9H92.USD","LU2360106780.USD","LU1261432733.SGD","LU0234572021.USD","LU2065170008.USD","LU1861127337.USD","SG9999015986.USD","LU0157215616.USD","LU0528227936.USD","BK4524","LU1868836914.USD","SG9999015978.USD","LU2552382058.USD","LU0079474960.USD","LU2764263203.CNY","IE00B7SZLL34.SGD","LU2461242641.AUD","BK4581","LU0648000940.SGD","LU1267930730.SGD","LU0345768740.USD","IE00BKDWB100.SGD","LU0642271901.SGD","LU0323591593.USD","LU2750360641.GBP","LU0175139822.USD","LU0072462426.USD","LU2023250504.SGD","BK4535","BK4554","BK4550","IE0004445239.USD","LU0215105999.USD","LU0957791311.USD","LU2357305700.SGD","LU2471134952.CNY","IE00BQXX3C00.GBP","LU1035775433.USD","LU1883839398.USD","LU1852331112.SGD","LU2087621335.USD","LU0494093205.USD","LU2237438978.USD","LU0312595415.SGD","LU0276348264.USD","LU0965509101.SGD","LU1232071149.USD","IE00BFSS8Q28.SGD","LU2168564495.EUR","IE00B3S45H60.SGD","LU0823421333.USD","LU1814569148.SGD","LU2065171311.SGD","LU0127658192.USD","LU0154236417.USD","LU0265550359.USD","LU1791710400.SGD","LU2362540622.SGD","LU1066053197.SGD","BK4585","LU0965509283.SGD","LU0786609619.USD","BK4220","IE00B775SV38.USD","LU1551013425.SGD","LU2054465674.USD","LU1720051108.HKD","LU0251132253.USD","LU2065169927.USD","LU2089283258.USD","IE00B19Z8X17.USD","IE00BKPKM429.USD","LU2125154935.USD","LU1201861165.SGD","HK0000914686.HKD","LU0211328371.USD","LU2471134796.USD","IE00BZ1G4Q59.USD","LU0302445910.USD","LU2092937148.SGD","IE00B7KXQ091.USD","LU1934455277.USD","LU0162691827.USD","LU1861559042.SGD","IE0034235303.USD","LU0053666078.USD","SRE","JBS","LU0210533765.USD","IE00B1XK9C88.USD","LU0265550946.USD","LU1069344957.HKD","LU0234570918.USD","LU1244550494.USD","IE00B4YYXB79.USD","LU2168564149.EUR","LU2756315318.SGD","LU0345774631.USD","LU1868836591.USD","BK4579","LU2764263039.SGD","LU1366192091.USD","LU1823568750.SGD","LU2083900584.USD","LU1145028129.USD","LU0107464264.USD","LU0077335932.USD","BK4503","LU0096364046.USD","LU1935043023.USD","LU2247934214.USD","SG9999014914.USD","LU2471134879.HKD","SG9999017495.SGD","LU0648001328.SGD","LU0354030511.USD","AMZN","SG9999004303.SGD","LU0683600562.USD","LU1815333072.USD","LU0310800379.SGD","LU1778281490.HKD","LU0080751232.USD","SIRI","LU0109391861.USD","LU1988902786.USD","LU0353189763.USD","LU0097036916.USD","LU2275660780.HKD","LU2028103732.USD","SGXZ23171101.USD","LU1037948897.HKD","LU0289960550.SGD","LU2430703178.SGD","LU0256863902.USD","LU2592432038.USD","LU1868836757.USD","IE0004445015.USD","LU2271345857.HKD","LU0466842654.USD","LU1267930573.SGD","BK4561","LU0820561818.USD","LU1804176565.USD","LU1989764664.SGD","LU0345769631.USD","LU0056508442.USD","LU1935042488.USD","LU2168564222.USD","BK4592","LU0130102774.USD","LU2250418816.HKD","LU1791710582.SGD","LU1316542783.SGD","LU2125154778.USD","LU2108987350.USD","LU1046421795.USD","LU1880398471.USD","LU2403377893.USD","IE00BFSS7M15.SGD","LU1861558580.USD","LU1366333091.USD","LU0823434583.USD","LU1037948541.HKD","LU2213496289.HKD","IE000W1ABFV2.USD","LU0158827948.USD","BK4122","SG9999015945.SGD","LU2168563687.JPY","SG9999014880.SGD","LU2471134523.USD","IE000YTNTUN2.SGD","LU1629891620.HKD","LU0689472784.USD","LU0348723411.USD","LU1496350502.SGD","LU1551013342.USD","IE0002270589.USD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","LU0208291251.USD","LU2242650005.HKD","IE00BJJMRY28.SGD","LU0965508806.USD","IE0004091025.USD","BK4588","LU1323610961.USD","LU0158827781.USD","LU2764262908.HKD","LU1880398554.USD","LU0308772762.SGD","LU0417517546.SGD","LU2211817866.USD","AZYY","LU2552382132.HKD","LU2746668974.SGD","LU0070302665.USD","LU2106854487.HKD","LU2463028550.USD","BK4566","SGXZ81514606.USD","LU1084165304.USD","BK4559","LU2097829019.USD","LU2896262040.SGD","LU0061475181.USD","LU0820562030.AUD","JMIA","LU0345770993.USD","LU0820561909.HKD","LU2077746001.SGD","LU0823411888.USD","LU2211815571.USD","SGXZ51526630.SGD","LU2756315664.SGD","LU2381873111.SGD","LU0070217475.USD","LU2746668461.USD","IE00B775H168.HKD","IE00BMPRXQ63.HKD","LU2092627202.USD","IE000ITXATA3.USD","SG9999002224.SGD","IE00B1BXHZ80.USD","LU0238689110.USD","LU2505996681.GBP","AMZW","IE00BMPRXR70.SGD","IE00B19Z3B42.SGD","LU0456855351.SGD","LU2602419157.SGD","LU0289941410.SGD","LU1718418525.SGD","LU1244550221.USD","BK4548","HK0000914660.USD","IE00B19Z8W00.USD","IE00B4JS1V06.HKD","GB00BDT5M118.USD","LU1280957306.USD","LU2417539215.USD","LU0788109477.HKD","LU2452424414.USD","IE00BJJMRX11.SGD","LU0096362180.USD","LU1868837300.USD","LU2750360997.AUD","LU1674673428.USD","LU0310799852.SGD","LU0724617625.USD","LU1267930490.SGD","LU2264538146.SGD","LU2236285917.USD","AMZZ","LU1633808545.USD","LU0029864427.USD","LU1548497426.USD","LU2023250330.USD","LU0198837287.USD"],"gpt_icon":1},{"id":"2601819819","title":"BUZZ--美國股票走勢-Shake Shack、Arrowhead 製藥公司、洛歇馬丁公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2601819819","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601819819?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 23:52","pubTimestamp":1767714728,"startTime":"0","endTime":"0","summary":".N美国东部时间10:30，道琼斯工业平均指数.DJI上涨0.42%，报49,184.92点。标普 500 指数.SPX上涨 0.42%，报 6,931.22 点；纳斯达克综合指数.IXIC上涨 0.49%，报 23,508.79 点。。nL4N3Y70PF ** CoreWeave Inc CRWV.O:BUZZ - 因 Truist 开始报道而获得 \"持有 \"评级；股价","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4S3Y710Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHAK","GNPX","HL","INTU","MCHP","OS","CORZ","ZETA","IMSR","ALMS","ALKS","O","ACN","NTRS","CDE","ACRS","VRTX","BAC","PNC","JXN","CFG","APGE","FERG","ALB","BALL","AEVA","EPAM","REGN","STAA","UAA","EQIX","STT","GILD","IFF","CRNX","DLR","TFC","LMT","NBP","ANGO","BK","VST","AIG","GL","NEM"],"gpt_icon":1},{"id":"2601818061","title":"BUZZ--美國股票走勢-Alkermes、Ball Corp、NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818061","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818061?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 22:12","pubTimestamp":1767708747,"startTime":"0","endTime":"0","summary":".N** 国际香精香料公司IFF.N：BUZZ - MS看好配料领域的 \"结构性赢家\"，减持帝斯曼股票，增持吉娃丹股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4T3Y70VL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNPX","NVDS.UK","2NVD.UK","RTO.UK","ZETA","ACRS","FERG","VERX","APGE","ALB","ACN","VST","GILD","JXN","ALMS","VRTX","OS","STT","CRNX","GL","NBP","O","NVDS","3NVD.UK","NVDU","REGN","NTRS","BALL","BK","AIG","INTU","MCHP","HGT.UK","ALKS","UAA","CDE","AEVA","HL","NVDX","NVDY","AU","NEM","IFF","NVD","ANGO"],"gpt_icon":1},{"id":"2601897551","title":"BUZZ-癌症藥物在早期試驗中顯示出前景，NovaBridge 公司業績上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897551","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897551?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:59","pubTimestamp":1767704399,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4T3Y70SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2601689260","title":"新橋生物公布Givastomig Ib期劑量擴展研究突破性成果；低至25美元/月，諾和諾德口服GLP-1上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2601689260","media":"氨基观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601689260?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:14","pubTimestamp":1767701642,"startTime":"0","endTime":"0","summary":"口服减重GLP-1上市。mRNA预防性疫苗新进展。3）新桥生物公布Givastomig最新Ib期研究数据1月6日，新桥生物宣布，其Claudin 18.2x 4-1BB双特异性抗体Givastomig联合纳武利尤单抗及化疗方案用于一线治疗HER2阴性转移的胃癌患者的Ib期联合疗法研究，取得积极的数据。/ 03 /海外药闻1）低至25美元/月，诺和诺德口服GLP-1上市！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106203538a4a3760d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106203538a4a3760d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4144","BK4599","NVO","NBP","LU1093756325.SGD","BK4007","BK4139","BK4532","LU0154236417.USD","LU1093756168.USD","BK4590","BK4588","BK4585"],"gpt_icon":1},{"id":"1119906453","title":"新橋生物聯合療法耐受性良好 安全性媲美現行標準治療方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1119906453","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119906453?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:13","pubTimestamp":1767701586,"startTime":"0","endTime":"0","summary":"新桥生物最新研究数据显示，其开发的联合治疗方案展现出优异的耐受性特征，安全性与当前标准治疗方案相当。该结果表明该疗法在维持疗效的同时，未增加额外安全性风险，为患者提供了更优的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"1133190087","title":"新橋生物聯合療法安全性特徵與既往觀察相似，免疫相關性胃炎引發關注","url":"https://stock-news.laohu8.com/highlight/detail?id=1133190087","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133190087?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:04","pubTimestamp":1767701071,"startTime":"0","endTime":"0","summary":"新桥生物最新研究数据显示，其联合疗法的整体安全性特征与早期观察结果基本一致。值得注意的是，研究中出现了免疫相关性胃炎病例，这一发现为后续临床监测提供了重要参考依据。研究人员指出，该不良反应属于已知免疫检查点抑制剂治疗的潜在风险范畴，目前所有病例均通过标准医疗干预得到有效控制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"1114840344","title":"新橋生物公布Givastomig聯合療法一線治療轉移性胃癌IB期劑量擴展積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1114840344","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114840344?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:04","pubTimestamp":1767701043,"startTime":"0","endTime":"0","summary":"新桥生物今日公布了其Givastomig联合疗法在IB期临床试验剂量扩展阶段的最新数据，该研究针对一线治疗转移性胃癌患者。\n数据显示，在剂量扩展队列中，Givastomig展现出令人鼓舞的临床活性与可控的安全性特征。这一积极进展为后续临床开发提供了重要依据。\n研究采用阶梯式剂量递增方案，逐步探索Givastomig与标准化疗联合使用的最佳治疗窗口。最新分析结果证实了该疗法在肿瘤缩小率和疾病控制率方面的潜在优势。\n目前，研究团队正进一步分析生物标志物数据，以识别最可能从该疗法中获益的患者群体。这些发现将为即将开展的注册性临床研究奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}